Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Efficacy and Side Effects of Sputnik V, Sinopharm and Astrazeneca Vaccines to Stop Covid-19; a Review and Discussion Publisher



Ghiasi N1 ; Valizadeh R2 ; Arabsorkhi M3 ; Hoseyni TS4 ; Esfandiari K4 ; Sadighpour T5, 6 ; Jahantigh HR7, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Midwifery, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
  2. 2. Student Research Committee, Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Medical Education Department, Medical Education Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Ali-Asghar Children Hospital, Department of Radiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Herbert Wertheim College of Medicine, Florida international university, FL, United States
  6. 6. American University of Antigua, College of Medicine, Antigua and Barbuda
  7. 7. Interdisciplinary Department of Medicine - Section of Occupational Medicine, University of Bari, Bari, Italy
  8. 8. Animal Health and Zoonosis PhD Course, Department of Veterinary Medicine, University of Bari, Bari, Italy

Source: Immunopathologia Persa Published:2021


Abstract

We believe that vaccination is just a way to eliminate or strongly stop the COVID-19. In this regard, there are several vaccines with different efficacy and side effects. It is urgently required to have some efficient vaccines for the prevention and control of SARS-CoV-2. In this review, international databases were considered for searching relevant articles from 1 January 2020 to 1 May 2021. Keywords were COVID-19, novel coronavirus, 2019-nCoV, coronavirus disease 2019, vaccine, Sputnik V, Gamaleya, Gam-COVID-Vac, Sinopharm, BBIBP-CorV, AstraZeneca, Vaxzevria, Oxford, ChAdOx1 nCoV-19 and AZD1222. Three Sputnik V, Sinopharm and AstraZeneca vaccines are useful to gain herd immunity. Enough intervals (at least three weeks/21 days) must be considered for sufficient neutralizing antibody titers. What is important is that the vaccination should be accelerated with each of the aforementioned three vaccines to achieve herd immunity in a shorter period of time because all three vaccines provide 100% prevention of severe COVID-19. © 2021 The Author(s);
Related Docs
View other Related Docs
1. A Comprehensive Review on Various Aspects of Sars-Cov-2 (Covid-19) Vaccines, International Journal of Preventive Medicine (2022)
2. Potential Treatments for Covid-19; a Narrative Literature Review, Archives of Academic Emergency Medicine (2020)
3. Covid-19 Vaccine Boosters: The Good, the Bad, and the Ugly, Vaccines (2021)
4. Cardiovascular Complications of Sars-Cov-2 Vaccines: An Overview, Cardiology and Therapy (2022)
5. Association of Prior Covid‑19 Infection With Risk of Breakthrough Infection Following Vaccination: A Cohort Study in Isfahan, Iran, International Journal of Preventive Medicine (2024)
6. Covid-19 Vaccines: Current and Future Challenges, Frontiers in Pharmacology (2024)
7. Importance of the Covid-19 Vaccine Booster Dose in Protection and Immunity, Vaccines (2022)
8. Vaccine-Associated Complications: A Comparative Multicenter Evaluation Among Dental Practitioners and Dental Students—Which Candidate Vaccine Is More Safe in Sars Cov Ii, Gam-Covid-Vac (Sputnik V), Chadox1 Ncov-19 (Astrazeneca), Bbv152 (Covaxin), or Bbibp-Corv(Sinopharm)?, Maxillofacial Plastic and Reconstructive Surgery (2022)
Experts (# of related papers)
View all Related Experts
Shaghayegh Haghjooy Javanmard (9)
Shahrzad Ahangarzadeh (5)
Other Related Docs
9. Cardiovascular Complications of Covid-19 Vaccines: A Review of Case-Report and Case-Series Studies, Heart and Lung (2023)
10. Vaccine Design and Delivery Approaches for Covid-19, International Immunopharmacology (2021)
11. Safety, Acceptance, and Hesitancy of Covid-19 Vaccines Among High-Risk Sub-Populations: A Narrative Review, Journal of Pediatrics Review (2023)
12. Sars-Cov-2, Sars and Mers: Three Formidable Coronaviruses Which Have Originated From Bats; [Sars-Cov-2, Sars-Cov I Mers-Cov: Trzy Grozne Koronawirusy Pochodzace Od Nietoperzy], Postepy Higieny i Medycyny Doswiadczalnej (2021)
13. Effectiveness of Corticosteroid Therapy in Patients With Moderate to Severe Coronavirus Disease 2019: A Retrospective Study, Journal of Nephropharmacology (2023)
14. A Prospective Cohort Study Protocol: Monitoring and Surveillance of Adverse Events Following Heterologous Booster Doses of Oxford Astrazeneca Covid-19 Vaccine in Previous Recipients of Two Doses of Sinopharm or Sputnik V Vaccines in Iran, BMC Public Health (2023)
15. Sars-Cov-2 Vaccines: A Double-Edged Sword Throughout Rapid Evolution of Covid-19, Cell Biology International (2022)
16. Efficacy and Safety of an Inactivated Virus-Particle Vaccine for Sars-Cov-2, Biv1-Coviran: Randomised, Placebo Controlled, Double Blind, Multicentre, Phase 3 Clinical Trial, BMJ (2023)
17. Aspects of Epidemiology, Pathology, Virology, Immunology, Transmission, Prevention, Prognosis, Diagnosis, and Treatment of Covid.19 Pandemic: A Narrative Review, International Journal of Preventive Medicine (2021)
18. Genetics and Genomics of Sars-Cov-2: A Review of the Literature With the Special Focus on Genetic Diversity and Sars-Cov-2 Genome Detection, Genomics (2021)
19. Covid-19 Management in the Emergency Ward, Journal of Research in Medical Sciences (2021)
20. Sars-Cov-2 (Covid-19): New Discoveries and Current Challenges, Applied Sciences (Switzerland) (2020)
21. Convalescent Plasma Therapy for Covid-19: Lessons From Sars-Cov, Mers-Cov, and H1n1 Infection, Acta Medica Indonesiana (2021)
22. Sars-Cov-2 Variant-Specific Mrna Vaccine: Pros and Cons, Viral Immunology (2023)
23. Epidemiological Review of the Coronavirus Disease 2019 (Covid-19) Pandemic up to 15 March 2020, Journal of Isfahan Medical School (2020)
24. Emerging Coronaviruses: First Sars, Second Mers and Third Sars-Cov-2. Epidemiological Updates of Covid-19, Infezioni in Medicina (2020)
25. Saliva As a Diagnostic Specimen for Detection of Sars-Cov-2 in Suspected Patients: A Scoping Review, Infectious Diseases of Poverty (2020)
26. Novel and Emerging Mutations of Sars-Cov-2: Biomedical Implications, Biomedicine and Pharmacotherapy (2021)
27. Current Status of Covid-19 Pandemic; Characteristics, Diagnosis, Prevention, and Treatment, Journal of Research in Medical Sciences (2020)
28. Covid-19 Breakthrough Infections Among Patients With Cancer Receiving Sinopharm Bibp Vaccine, International Journal of Cancer Management (2022)
29. A Narrative Literature Review on Traditional Medicine Options for Treatment of Corona Virus Disease 2019 (Covid-19), Complementary Therapies in Clinical Practice (2020)
30. Hyper-Immune Bovine Milk As an Immunological and Nutritional Supplement for Covid-19, Frontiers in Nutrition (2022)
31. Controlling and Prevention of Novel Coronavirus Through Health and Safety Protocols in Food: Review Article, Tehran University Medical Journal (2021)
32. Pi3k/Akt/Mtor Pathway: A Potential Target for Anti-Sars-Cov-2 Therapy, Immunologic Research (2022)
33. Epidemiological Study of Covid-19 in Iran and the World: A Review Study, Infectious Disorders - Drug Targets (2022)
34. Differential Diagnostic Utility of Clinical Laboratory Data in Patients With Severe and Non-Severe Covid-19, Shiraz E Medical Journal (2022)
35. Covid19 Prevention & Care; a Cancer Specific Guideline, Archives of Iranian Medicine (2020)
36. Evaluation of Anti-Sars-Cov-2 Rbd Antibody Response After Booster Dose of Spikogen® in Individuals With Two Previous Doses of Sinopharm and Its Association With Hla-Dr and -Dq Alleles, Human Immunology (2025)
37. A Review on the Diagnostic Approaches of Covid-19 Infection; Features and Limitations, Journal of Isfahan Medical School (2021)
38. Exploring the Out of Sight Antigens of Sars-Cov-2 to Design a Candidate Multi-Epitope Vaccine by Utilizing Immunoinformatics Approaches, Vaccine (2020)
39. The Covid-19 Pandemic: A Systematic Review of the Current Evidence; [Пандемия Covid-19: Систематический Обзор Современных Данных], Russian Journal of Infection and Immunity (2020)
40. Monitoring and Active Surveillance of Adverse Events Following the Booster Dose of Azd1222 Vaccine in People Vaccinated With Sinopharm Bbibp-Corv: A Cohort Study, BMC Public Health (2025)
41. Outcomes of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia After the Acute Phase, Stroke (2022)
42. The Effect of Covid-19 Vaccination on Reducing the Risk of Infection, Hospitalization, and Death in Isfahan Province, Iran, Iranian Journal of Public Health (2022)
43. Prevention of Covid-19: Preventive Strategies for General Population, Healthcare Setting, and Various Professions, Advances in Experimental Medicine and Biology (2021)
44. Sars-Cov-2 Serology Among People With Multiple Sclerosis on Disease-Modifying Therapies After Bbibp-Corv (Sinopharm) Inactivated Virus Vaccination: Same Story, Different Vaccine, Multiple Sclerosis and Related Disorders (2022)
45. Recent Findings of Coronavirus: The Pathogenesis and Treatment, Journal of Isfahan Medical School (2020)
46. Co-Infection Between the Severe Acute Respiratory Syndrome Coronavirus 2 and the Influenza Type B in Isfahan, Iran, Journal of Research in Medical Sciences (2021)
47. A Comprehensive Review of Therapeutic Options for Covid-19, Ethiopian Journal of Health Development (2022)
48. Chitin and Chitosan As Tools to Combat Covid-19: A Triple Approach, International Journal of Biological Macromolecules (2021)
49. Covid-19 Infection Risk Following Elective Arthroplasty and Surgical Complications in Covid-19-Vaccinated Patients: A Multicenter Comparative Cohort Study, Arthroplasty Today (2022)
50. Outlook of Therapeutic and Diagnostic Competency of Nanobodies Against Sars-Cov-2: A Systematic Review, Analytical Biochemistry (2022)